| Patient | Billie Holiday |
|---|---|
| Date of birth | 1993-04-07 |
| Identifiers | MRN HR-ML010-SYN; SSN (made up) 000-10-4472 |
| Document date | 2026-04-20 |
| Author | Constance Mayfield, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Establishing primary care five weeks after release from custody: medication for opioid use disorder, overdose prevention, alcohol care, liver and infection screening, and depression and safety screening [S]
This fictional modern episode addresses the presenting concerns below. [S]
Historical basis. These claims are historical evidence, not findings from a modern examination.
3 later historical claims are omitted because they describe events after the index age. See the teaching note.
Historical biography with true dates. These events are not part of the synthetic care timeline.
| Historical date | History | Evidence |
|---|---|---|
| about 1943 | Heroin use from the early 1940s, becoming a severe addiction in the late 1940s; sought treatment for it at least once | D (CLM-0003, CLM-0005) |
| October 1945 | Heavier drinking and increased drug use after her mother's death | D (CLM-0002) |
| March 16, 1948 | Federal custody after a narcotics possession conviction, about ten months with enforced abstinence; released early | D (CLM-0004) |
| Relative | Condition | Age at death | Evidence |
|---|---|---|---|
| mother | Died in 1945; cause not recorded in the cited source | D (CLM-0002) |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Buprenorphine 8 mg and naloxone 2 mg sublingual film: half a film (4 mg) on day 1, then one film (8 mg) under the tongue daily | One film under the tongue daily after a 4 mg first dose | Sublingual route | 2026-04-20 to 2026-04-27 | completed | S |
| Naloxone 4 mg nasal spray, one spray in one nostril for a suspected opioid overdose; may repeat every 2 to 3 minutes in alternating nostrils; call 911 | One spray (4 mg) in one nostril for suspected overdose; repeat every 2 to 3 minutes if there is no response | Nasal route | 2026-04-20 | active | S |
| Thiamine 100 mg oral tablet, one tablet by mouth daily | One tablet by mouth daily | Oral route | 2026-04-20 to 2026-10-19 | completed | S |
Positive for the concerns in the history of present illness. Alert, guarded at first and then candid; speech normal; no signs of intoxication or withdrawal. Mood low and tired, with grief for her mother that still returns; PHQ-9 score 9 with item 9 scored 0; no thoughts of suicide or self-harm. No other systems reported as affected in this synthetic episode. [S]
Alert and engaged. Independent in all activities; performing several nights a week; sleep broken since release. [S]
Vital signs recorded on 2026-04-20; see the Vital Signs section. Mental status: Alert, guarded at first and then candid; speech normal; no signs of intoxication or withdrawal; Mood low and tired, with grief for her mother that still returns; PHQ-9 score 9 with item 9 scored 0; no thoughts of suicide or self-harm. The physical examination is limited to the findings relevant to this synthetic episode. [S]
Structured safety assessment: current ideation absent, intent absent, plan absent, access to means reviewed: yes. Outpatient care. Overdose risk is high in the weeks after release because tolerance has fallen: naloxone for her and her friend, never using alone, testing any drug supply with fentanyl test strips, and buprenorphine started today. The 988 Suicide & Crisis Lifeline was given and saved in her phone, and a written safety plan was made with her. Safety reviewed at every visit. [S]
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-04-20 | Body height | 165 | cm | S |
| 2026-04-20 | Body weight | 68 | kg | S |
| 2026-04-20 | Body mass index (BMI) [Ratio] | 25 | kg/m2 | S |
| 2026-04-20 | Systolic blood pressure | 126 | mm[Hg] | S |
| 2026-04-20 | Diastolic blood pressure | 80 | mm[Hg] | S |
| 2026-04-20 | Heart rate | 84 | /min | S |
| 2026-04-20 | Respiratory rate | 16 | /min | S |
| 2026-04-20 | Body temperature | 36.8 | Cel | S |
| 2026-04-20 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-04-20 | Hemoglobin [Mass/volume] in Blood | 12.4 | g/dL | 11.6-15 g/dL | Normal | S |
| 2026-04-20 | MCV [Entitic mean volume] in Red Blood Cells by Automated count | 101 | fL | 80-100 fL | High | S |
| 2026-04-20 | Platelets [#/volume] in Blood by Automated count | 236 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 2026-04-20 | Sodium [Moles/volume] in Serum or Plasma | 138 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-04-20 | Potassium [Moles/volume] in Serum or Plasma | 4 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-04-20 | Creatinine [Mass/volume] in Serum or Plasma | 0.72 | mg/dL | 0.59-1.04 mg/dL | Normal | S |
| 2026-04-20 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 113 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-04-20 | Glucose [Mass/volume] in Serum or Plasma | 88 | mg/dL | 70-99 mg/dL | Normal | S |
| 2026-04-20 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 52 | U/L | 10-40 U/L | High | S |
| 2026-04-20 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 38 | U/L | 7-56 U/L | Normal | S |
| 2026-04-20 | Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma | 84 | U/L | 5-40 U/L | High | S |
| 2026-04-20 | Albumin [Mass/volume] in Serum or Plasma | 4 | g/dL | 3.5-5 g/dL | Normal | S |
| 2026-04-20 | Bilirubin.total [Mass/volume] in Serum or Plasma | 0.7 | mg/dL | 0.1-1.2 mg/dL | Normal | S |
| 2026-04-20 | Hepatitis C virus Ab Signal/Cutoff in Serum or Plasma by Immunoassay | 0.09 | {s_co_ratio} | Below 1.00 is nonreactive | Normal | S |
| 2026-04-20 | Hepatitis B virus surface Ab [Units/volume] in Serum | 3 | m[IU]/mL | >=10 m[IU]/mL | Low | S |
| 2026-04-20 | Phosphatidylethanol [Mass/volume] in Blood | 312 | ng/mL | Below 20 ng/mL: abstinence or light drinking; 20 to 199: significant drinking; 200 or more: heavy drinking | High | S |
| 2026-04-20 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 9 | {score} | S | ||
| 2026-04-20 | Total score [AUDIT-C] | 8 | {score} | S | ||
| 2026-04-20 | Total score [DAST-10] | 7 | {score} | S |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Opioid use disorder (heroin), severe; in early remission in a controlled environment at intake, five weeks after release from custody; on buprenorphine; synthetic modern episode linked to her documented heroin use | active | confirmed | F11.20 | S — Synthetic modern coding of the documented heroin addiction; language is person-first, and the code does not change with a return to use. |
| Alcohol use disorder, moderate; synthetic modern episode linked to her documented heavier drinking after her mother's death | active | confirmed | F10.20 | S — Synthetic modern coding of the documented drinking; the liver disease reported in her last year is not coded, because it was documented long after the episode. |